Form 4: Apellis Pharmaceuticals CFO Granted Significant Stock Option Award

Apellis Pharmaceuticals, Inc.'s Chief Financial Officer, Timothy Eugene Sullivan, was granted 82,500 stock options with an exercise price of $19.39, vesting over a two-year period.

Summary

• Timothy Eugene Sullivan, Chief Financial Officer of Apellis Pharmaceuticals, Inc. (APLS), was granted 82,500 stock options.
• The stock options were granted on June 9, 2025, with an exercise price of $19.39 per share.
• The options have an expiration date of June 9, 2035.
• The vesting schedule for these options is 50% on the one-year anniversary of the grant date and the remaining 50% on the two-year anniversary of the grant date.
• Vesting is contingent upon Mr. Sullivan's continued service with the company.

Sentiment

Score: 7

Explanation: The sentiment is positive as the stock option grant is a standard and beneficial executive compensation practice that aligns management's interests with shareholder value. It does not indicate any negative operational or financial news.

Positives

• The grant of stock options aligns the Chief Financial Officer's long-term incentives with shareholder value, encouraging sustained performance and commitment.
• This is a standard executive compensation practice, indicating stability in management and a commitment to retaining key personnel.

Risks

• The vesting of the stock options is contingent upon continued service, meaning the options could be forfeited if the CFO's employment ceases before the vesting dates.

Future Outlook

The stock option grant incentivizes the Chief Financial Officer's future performance and continued service, aligning his financial interests with the long-term success of Apellis Pharmaceuticals. No specific forward-looking financial guidance or operational outlook is provided in this filing.

Industry Context

The granting of stock options to key executives like the Chief Financial Officer is a common and widely accepted practice across the biotechnology and pharmaceutical industries. It serves as a critical component of executive compensation packages, designed to attract, retain, and motivate top talent by linking their personal wealth directly to the company's stock performance.

Comparison to Industry Standards

• Granting stock options to executives is a standard compensation practice in the biotechnology and pharmaceutical sectors, comparable to practices at companies like Biogen Inc. or Vertex Pharmaceuticals Inc., which frequently use equity awards to incentivize leadership.
• The vesting schedule of 50% after one year and 50% after two years is a common structure for executive equity grants, aiming to ensure retention and long-term commitment, similar to vesting schedules observed in many peer companies.

Related Party Transactions

• The grant of 82,500 stock options to Timothy Eugene Sullivan, the Chief Financial Officer, constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: The grant aligns the CFO's financial interests with the company's stock performance, potentially leading to better long-term value creation.
• Employees (CFO): The grant provides a significant incentive for the CFO to remain with the company and contribute to its success.

Next Steps

• The stock options will vest in two tranches: 50% on June 9, 2026, and the remaining 50% on June 9, 2027, contingent on continued service.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, Stock Options, Executive Compensation, Form 4, Timothy Sullivan, Chief Financial Officer, Equity Grant, Insider Transaction